Why I’d avoid Indivior plc today after shares crash 35%

Indivior plc (LON: INDV) is one of today’s major fallers.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Indivior (LSE: INDV) has seen over £1bn wiped off its market capitalisation today following news concerning potential generic competition. The pharmaceutical company’s share price has fallen by 35% as investors have reacted negatively to the outcome of a US court ruling.

Looking ahead, more pain could arise out of the ruling and this may negatively impact the company’s financial outlook. As such, it seems to be a stock to avoid at the present time.

Ruling

The ruling by the District Court of Delaware concerns possible generic competition to the company’s key product, Suboxone Film. It is used to treat opioid addiction and makes up the majority of the company’s revenues. The court has decided that a generic competitor to the treatment, Indian-based Dr Reddy’s, does not infringe on Indivior’s patents.

Should you invest £1,000 in Indivior Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Indivior Plc made the list?

See the 6 stocks

As such, pending FDA approval, a competitor to Suboxone could be on the market in the near term. This would be very likely to slash sales of Suboxone Film and would lead to lower sales and profitability for the company in future. This could be as much as an 80% fall in sales according to the company.

Outcome

As well as potentially causing sales of Suboxone Film to fall, the ruling also means that Indivior may find it more difficult to fight future battles regarding its patents. In the past, it has been successful in fighting off other generic competition, but the ruling could set a precedent which makes it easier for generic competitors to launch rival drugs.

Indivior’s financial guidance is now likely to change dramatically. Although it states in today’s update that it intends to appeal the decision by the court, it had assumed there would be no generic competition to Suboxone when formulating its financial guidance. Therefore, the company’s share price could yet fall further if forecasts are even lower than investors currently anticipate.

Certainly, the company may have contingency plans in place should generic competition emerge. The reality though, is that if FDA approval is granted for Dr Reddy’s rival drug then the company’s sales are very likely to decline significantly.

Risks

Of course, this is not the first time that there has been a surprise announcement regarding patent infringement. In the boom/bust pharmaceutical industry all major companies must face the reality of a loss of patents at some point in their lifetime. However, in the case of Indivior, Suboxone is its major drug by sales. It is therefore heavily reliant on it and lacks the diversity of other major pharmaceutical companies. For other companies, the loss of a patent would be hugely disappointing, but could be offset by other products. For Indivior, that may not be the case.

Therefore, with investor sentiment declining rapidly and the company facing a highly uncertain future, now does not seem to be the right time to buy it. In time, there may be a buying opportunity. But right now, it appears to be a stock to avoid.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Indivior Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Indivior Plc made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens has no position in any of the companies mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

Can the Lloyds share price surge even higher in 2025?

The Lloyds share price has been on a tearing run of late. Ken Hall has his say on the stock's…

Read more »

Two business people sitting at cafe working on new project using laptop. Young businesswoman taking notes and businessman working on laptop computer.
Investing Articles

The FTSE 100 is at record highs, but these stocks still look cheap to me

The FTSE 100’s latest surge has left these well-known stocks behind. Roland Head explains why these unloved firms have caught…

Read more »

Light trails from traffic moving down The Mound in central Edinburgh, Scotland during December
Investing Articles

2 top growth stocks that could help drive Scottish Mortgage higher by 2030! 

Ben McPoland thinks these two US growth stocks are among the most exciting in this FTSE 100 investment trust's portfolio.

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Over the next 10 years, I think I’ll make money from these 3 stocks in my ISA

Our writer highlights a trio of different companies from his Stocks and Shares ISA that he thinks will benefit from…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

£10,000 invested in BT shares in May 2024 is now worth…

BT shares have been on the up since a potentially pivotal event just over a year ago. Are we just…

Read more »

Group of friends meet up in a pub
Investing Articles

1 FTSE 250 stock I just can’t stop buying

While UK bars and restaurants are under pressure, the pub industry is doing well. And Stephen Wright is enjoying the…

Read more »

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

A PEG ratio of 1.15 and tonnes of IP: here’s why Nvidia stock still looks cheap

Nvidia stock is trading near its highs once again, and while it’s not as cheap as it was, Dr James…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

The Ashtead share price steadies ahead of US listing move. What should investors do now?

The Ashtead share price has soared 12,000% since 1988 in its life on the FTSE 100. As FY results come…

Read more »